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Abstract
Heparanase (HPA), an endo-h-D-glucuronidase that cleaves the heparan sulfate chain of heparan sulfate proteoglycans, is
overexpressed in majority of human cancers. Recent evidence suggests that small interfering RNA (siRNA) induces
transcriptional gene silencing (TGS) in human cells. In this study, transfection of siRNA against 29/+10 bp (siH3), but not
2174/2155 bp (siH1) or 2134/2115 bp (siH2) region relative to transcription start site (TSS) locating at 101 bp upstream of
the translation start site, resulted in TGS of heparanase in human prostate cancer, bladder cancer, and gastric cancer cells in
a sequence-specific manner. Methylation-specific PCR and bisulfite sequencing revealed no DNA methylation of CpG islands
within heparanase promoter in siH3-transfected cells. The TGS of heparanase did not involve changes of epigenetic markers
histone H3 lysine 9 dimethylation (H3K9me2), histone H3 lysine 27 trimethylation (H3K27me3) or active chromatin marker
acetylated histone H3 (AcH3). The regulation of alternative splicing was not involved in siH3-mediated TGS. Instead, siH3
interfered with transcription initiation via decreasing the binding of both RNA polymerase II and transcription factor II B
(TFIIB), but not the binding of transcription factors Sp1 or early growth response 1, on the heparanase promoter. Moreover,
Argonaute 1 and Argonaute 2 facilitated the decreased binding of RNA polymerase II and TFIIB on heparanase promoter,
and were necessary in siH3-induced TGS of heparanase. Stable transfection of the short hairpin RNA construct targeting
heparanase TSS (29/+10 bp) into cancer cells, resulted in decreased proliferation, invasion, metastasis and angiogenesis of
cancer cells in vitro and in athymic mice models. These results suggest that small RNAs targeting TSS can induce TGS of
heparanase via interference with transcription initiation, and significantly suppress the tumor growth, invasion, metastasis
and angiogenesis of cancer cells.
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Introduction
Heparanase is an endo-h-D-glucuronidase that has the ability to
cleave the heparan sulfate chain of heparan sulfate proteoglycans
[1], and facilitates the invasion and metastasis of tumor cells by
deteriorating the basement membrane (BM) and extracellular
matrix barriers [2]. Heparanase also contributes to angiogenesis
by releasing and activating various heparan sulfate-binding growth
factors [3,4]. Moreover, high expression of heparanase is
frequently observed in an increasing number of primary human
tumors, such as prostate cancer, bladder cancer and gastric cancer,
and the heparanase-facilitated invasion and metastasis induce poor
outcomes in cancer patients [5–8]. These studies suggest that
heparanase may be served as a molecular target for cancer
therapy.
Silencing of gene expression using small interfering RNA
(siRNA) represents a potential strategy for therapeutic product
development [9]. In addition to posttranscriptional gene silencing
in a wide variety of organisms, siRNA can interact with DNA
methyltransferase 3A (DNMT3A) and direct transcriptional gene
silencing (TGS) in human cells [10]. Promoter-targeted siRNAs
induce the CpG island methylation of ubiquitin C gene [11],
human immunodeficiency virus type 1 long terminal repeat [12],
Ras association domain family 1A [13], and interleukin-2 [14] in
human cells. In addition, exogenous siRNAs trigger TGS in
human cells through heterochromatin formation at target
promoter, involving recruitment of chromatin-modifying enzymes
to result in dimethylation of histone H3 at lysine 9, trimethylation
of histone H3 at lysine 27, and histone deacetylation [10,11,12].
Moreover, siRNAs targeting intronic or exonic sequences close to
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31379an alternative exon can increase the dimethylation of histone H3
at lysine 9 and trimethylation of histone H3 at lysine 27 at the
target site, resulting in differential splicing of that exon [15]. These
studies suggest that siRNAs affect not only transcription but also
splicing process of target gene, implying a feasible approach to
develop gene-specific therapeutics.
Transcription start sites (TSS) are essential switches for
converting recognition of DNA genome into active synthesis of
RNA copies [16]. Vlodavsky et al. identified the TSS of heparanase
gene at the nucleotide position 99 bp upstream of the translation
start site (ATG) by a traditional rapid amplification of cDNA ends
(RACE) assay [17]. By using the modified RLM-RACE method to
selectively amplify the DNA fragment from capped full-length
mRNA, Jiang et al. reported the accurate TSS at 101 bp upstream
of the ATG [18]. Alternative larger heparanase transcript has also
been noted in human immune system, however, the exact location
and upstream promoter of its TSS remain largely unknown [19–
21]. In the current study, we showed that small RNAs targeting
heparanase TSS locating at 101 bp upstream of the translation
start site [18], including siRNA and short hairpin RNA (shRNA),
induced TGS of heparanase via interfering with transcription
initiation, but not through inducing heterochromatin formation or
epigenetic changes, and attenuated the proliferation, invasion,
metastasis and angiogenesis of different kinds of cancer cells in vitro
and in vivo.
Results
siRNA-induced TGS of heparanase
To examine whether siRNA could induce TGS of heparanase,
we designed and synthesized three siRNAs targeting TSS (locating
at 101 bp upstream of the ATG) or more upstream regions of
heparanase promoter, 2174/2155 (siH1), 2134/2115 (siH2),
and 29/+10 bp (siH3) (Fig. 1A and Fig. S1). The siRNA targeting
the encoding region +1496/+1515 bp (siH4) was applied as a
control (Fig. 1A). Cell lines of most common human cancers,
including prostate cancer (PC-3), bladder cancer (EJ) and gastric
cancer (SGC-7901), were chosen as models for this study.
Transfection of siH3 and siH4, but not of siH1, siH2 or negative
control siRNA (siNC), attenuated the heparanase expression in
PC-3, EJ and SGC-7901 cells (Fig. 1B). In addition, transfection of
siH3, but not of siNC or scrambled siRNA (siSCb), abolished the
transcriptional and translational levels of heparanase in a dose-
dependent manner (Fig. 1C). The siH3-induced silencing of
heparanase lasted up to 5 days, and partially recovered at day 7
(Fig. 1D). Transfection of siM31 and siM32, two mismatched
siRNAs of siH3, did not abolish the heparanase expression
(Fig. 1E), demonstrating that the interference was executed by
siH3 in a sequence-dependent manner. The failure of siM32 to
inhibit transcription also indicated that partial complementarity to
the 59-terminus of mRNA was not sufficient for heparanase
silencing (Fig. 1E). DNA duplexes analogous to siH3 did not
inhibit expression, indicating that recognition must be mediated by
RNA (Fig. 1E). Promoter reporter-luciferase assay showed that
transfection of siH3, but not siScb, siM31 or siM32, suppressed the
heparanase promoter activity and transcription (Fig. 1F), suggest-
ing that the reduced heparanase expression was due to
transcriptional inhibition by siH3. Moreover, the expression of
non-downstream genes of heparanase, proliferating cell nuclear
antigen (PCNA) and cyclin D1, was not affected by transfection of
siH3 (Fig. S2). These results indicated that siH3 selectively
targeted the TSS and induced TGS of heparanase in a
sequence-specific manner in human cancer cells.
siRNA-induced inhibition of transcription initiation of
heparanase
Since TGS is associated with epigenetic changes of promoter,
such as DNA methylation, histone methylation, and histone
deacetylation [10,11,12], we first analyzed the epigenetic status of
upstream regions of heparanase promoter. The CpG islands were
unmethylated in untransfected PC-3, EJ and SGC-7901 cells
(mock) and in those transfected with siNC (data not shown).
Transfection of siH1, siH2 or siH3, did not induce the methylation
of CpG islands of heparanase promoter in cancer cells (Fig. 2A
and Fig. 2B). The expression and DNA binding of histone H3
lysine 9 dimethylation (H3K9me2) and histone H3 lysine 27
trimethylation (H3K27me3) on the heparanase promoter, two
repressive epigenetic marks involved in TGS [10], did not change
upon transfection of siH2, siH3, siH4 or siScb (Fig. S3 and
Fig. 2C). Moreover, the binding of acetylated histone H3 (AcH3),
a marker of transcriptionally active chromatin [22], was unaffected
by transfection with these siRNAs (Fig. 2C). Meanwhile, there
were no PCR products for ‘‘no-antibody’’ control in chromatin
immunoprecipitation (ChIP) assay (Fig. 2C). The binding of
H3K9me2 and H3K27me3 was enriched on the promoter of
transcriptionally silenced genes p16 and retinoic acid receptor beta
2 (RARb2) [23], when compared to that on heparanase promoter
in PC-3 cells (Fig. 2D), and the binding of AcH3 on the
heparanase promoter significantly increased after the pan histone
deacetylases (HDAC) inhibitor trichostatin A (TSA) treatment
(Fig. 2E), confirming the adequacy of ChIP assay conditions. In
addition, treatment of cancer cells with the DNMT inhibitor 5-
aza-29-deoxycytidine (5-Aza-CdR) or TSA did not affect hepar-
anase silencing, indicating that DNMTs and HDACs were
unlikely to be involved in this process (Fig. 2F). Furthermore,
ChIP assay revealed no changes in the binding of transcription
factors early growth response 1 (EGR1) and Sp1 on the
heparanase promoter region surrounding the siH3-targeted site,
ruling out their potential roles in the siH3-induced TGS of
heparanase (Fig. 2G). However, the decreased binding of RNA
polymerase II (RNA Pol II) on heparanase promoter was noted in
siH3-transfected cells, but not in siH2-, siH4- or siScb-transfected
cells (Fig. 2H). Moreover, the binding of transcription factor II B
(TFIIB) that directs RNA Pol II to the core promoter, was also
decreased in siH3-transfected cells (Fig. 2H). ChIP data on RNA
Pol II or TFIIB binding were confirmed by real-time quantitative
PCR (qPCR) with primers spanning the TSS (Fig. 2H). Decreased
RNA Pol II or TFIIB binding was seen up to 7 days after
transfection (Fig. 2I). In addition, the relative inclusion-to-
exclusion ratio of the first exon of heparanase, which was an
alternative exon near the siH3-targeted site, did not change after
transfection of siH2, siH3, siH4 or siScb in cancer cells (Fig. 2J),
suggesting that the regulation of alternative splicing was not
involved in siH3-mediated TGS. These results demonstrated that
transcription initiation of heparanase was interfered by the siH3
targeting TSS.
Involvement of Ago1 and Ago2 in siH3-induced
transcriptional inhibition of heparanase
Since previous studies indicated the involvement of RNA
interference (RNAi) machinery in TGS, we further explored the
influence of Argonaute 1 (Ago1) and Argonaute 2 (Ago2), two
integral components of the RNAi pathway [24,25], on siH3-
induced TGS of heparanase. As shown in Fig. 3A and Fig. 3B,
knocking down of Ago1 or Ago2 suppressed the siH3-induced
TGS of heparanase. Moreover, transfection of siH3, but not of
siScb, increased the association of Ago1 and Ago2 on the
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knocking down of Ago1 and Ago2 (Fig. 3C and Fig. 3D). In
addition, Ago1 or Ago2 silencing increased the binding of RNA
Pol II and TFIIB on heparanase promoter, whereas transfection of
siNC did not have any effect (Fig. 3E). Nuclear run-on assay
further demonstrated that the upstream transcribed mRNA
(containing Exon 1) presented at a low level compared to total
heparanase mRNA, and transfection of siH3 attenuated the
nascent transcription of total heparanase mRNA, but not the
mRNA initiated from upstream alternative TSS, which was also
restored by knocking down of Ago1 or Ago2, indicating that the
reduced heparanase expression was due to inhibition on the
transcription initiated from the downstream TSS (Fig. 3F). These
results indicated that Ago1 and Ago2 were necessary for siH3-
induced transcriptional inhibition of heparanase in human cancer
cells.
RNAi machinery interacted indirectly with transcription
preinitiation complex in siH3-induced TGS of heparanase
Since recent evidence shows an intricate interaction between the
RNAi machinery and RNA Pol II in heterochromatic silencing in
Drosophila [26], we hypothesize that Ago1 or Ago2 may directly
interact with RNA Pol II or TFIIB to participate in siH3-induced
TGS of heparanase. Consistent with previous studies [27,28], co-
immunoprecipitation analysis indicated that RNA Pol II interact-
ed with TFIIB in cultured cells. Transfection of siH3 did not
attenuate the interaction between RNA Pol II and TFIIB (Fig. 4A).
However, anti-RNA Pol II or anti-TFIIB antibodies did not co-
immunoprecipite Ago1 or Ago2 from siH3-transfected cells
(Fig. 4A), which was further evidenced by co-immunoprecipitation
analysis with pull-down by anti-Ago1 or anti-Ago2 antibodies
(Fig. 4B). Combining with above evidence that Ago1 and Ago2
influenced the binding of RNA Pol II and TFIIB on heparanase
promoter, these results indicated that RNAi machinery and
transcription preinitiation complex were associated, but not
directly interactive, in siH3-induced TGS of heparanase in human
cancer cells.
Heparanase TSS-targeted shRNA attenuated the
proliferation, adhesion, invasion and angiogenesis of
cancer cells in vitro
Because recent studies indicate the feasibility of shRNA-
mediated TGS in mammalian cells [29,30], in order to further
investigate the effects of heparanase TSS-targeted siRNA on
cancer cells, the shRNA constructs were established and
transfected into PC-3, EJ and SGC-7901 cells (Fig. S4A). Stable
transfection of shP3 (29/+10 bp) and shCd (+1496/+1515 bp),
but not of shP2 (2134/2115 bp) or scrambled shRNA (shScb),
resulted in attenuated mRNA and protein levels of heparanase
(Fig. S4B, and Fig. S4C), and decreased in vitro proliferation of
cancer cells (Fig. 5A, Fig. 5B and Fig. 5C). Transwell analysis
showed that the cells transfected with shP3 or shCd, but not with
shP2 or shScb, presented an impaired invasion capacity (Fig. 5D
and Fig. 5E). In addition, cancer cells transfected with shP3 or
shCd, but not with shP2 or shScb, exhibited markedly reduced
abilities in adhesion to the precoated matrigel (Fig. 5F). The tube
formation of endothelial cells was suppressed by treatment with
the medium preconditioned by stable transfection of cancer cells
with shP3 or shCd, but not with shScb (Fig. 5G and Fig. 5H).
Moreover, the release of basic fibroblast growth factor (bFGF)
from cancer cells was attenuated after stable transfection of shP3
or shCd, but not of shScb (Fig. 5I). These results indicated that
stable transfection of heparanase TSS-targeted shRNA remark-
ably decreased the proliferation, adhesion, invasion and angio-
genesis of cancer cells in vitro.
Heparanase TSS-targeted shRNA inhibited the growth,
metastasis and angiogenesis of cancer cells in vivo
We next investigated the efficacy of shP3 against tumor growth,
metastasis and angiogenesis in vivo. Stable transfection of shP3 or
shCd into PC-3 cells, resulted in decreased growth and weight of
subcutaneous xenograft tumors in athymic nude mice (Fig. 6A). In
addition, stable transfection of shP3 or shCd resulted in decrease
in CD31-positive microvessels and mean vessel density within
tumors (Fig. 6B). Moreover, the expression of heparanase
downstream genes within tumors, vascular endothelial growth
factor (VEGF) and matrix metallopeptidase 9 (MMP-9), was also
reduced by stable transfection of shP3 or shCd (Fig. 6C and
Fig. 6D).
In the peritoneal metastasis studies, nude mice that received
injection of PC-3 cells stably transfected with shCd or shP3
showed comparatively fewer nodules (2269 and 1767, respec-
tively) than empty vector (mock) group (106631) (Fig. 6E). In the
experimental metastasis studies, PC-3 cells stably transfected with
shP3 or shCd established statistically fewer lung metastatic
colonies than mock group (Fig. 6F). Combined with the similar
findings in EJ and SGC-7901 cells (data not shown), these results
suggested that heparanase TSS-targeted shRNA could inhibit the
growth, metastasis and angiogenesis of cancer cells in vivo.
Discussion
The TGS pathway was initially reported in tobacco plants, as
the state of methylation and expression of genes were demon-
strated to be affected by RNAs [31]. Recently, RNAs have been
reported to mediate TGS in mammalian cells via DNA CpG
methylation and heterochromatin formation [10,11,12,32]. The
silent-state epigenetic modifications cause the loss of transcription
factors recruitment [12,33]. Meanwhile, siRNAs targeting internal
gene regions of human fibronectin 1 can inhibit internal
elongation and subsequently affect splice site selection [15]. The
human heparanase promoter is consisted of a minimal basic region
that spans 300–700 bp proximally to the TSS locating at 101 bp
Figure 1. TSS-targeted siRNA abolishes the heparanase expression in cancer cells. A, scheme of siRNAs targeting TSS (locating at 101 bp
upstream of the translation start site), upstream promoter and encoding regions of heparanase, including siH1 (2174/2155 bp), siH2 (2134/
2115 bp), siH3 (29/+10 bp) and siH4 (+1496/+1515 bp). Automated nucleotide basic local alignment search tool (BLAST) searches demonstrated
that there was no sequence similar to siH1, siH2, or siH3 in the transcribed sequence of heparanase. B, 72 hrs post-transfection of siRNAs into PC-3, EJ
and SGC-7901 cells, 100 nmol/L siH3 or siH4, but not of siH1, siH2 or siNC, attenuated the heparanase expression in cancer cells. C, 72 hrs post-
transfection of siH3, but not of siNC or siScb, resulted in abolished heparanase expression of cancer cells in a dose-dependent manner. D, siH3
(100 nmol/L)-induced gene silencing of heparanase in cancer cells lasted up to 5 days, and partially restored at day 7. E, 72 hrs post-transfection of
100 nmol/L DNA duplexes analogous to siH3, siM31 or siM32 (two mismatched siRNAs of siH3), did not abolish the heparanase expression in cancer
cells. F, dual-luciferase reporter assay indicated that 72 hrs post-transfection of siH3, but not of siScb, siM31 or siM32, suppressed the heparanase
promoter activity and transcription in cancer cells. The symbols (# and D) indicate a significant decrease from untransfected control (mock) and a
significant increase from pGL3/Basic, respectively.
doi:10.1371/journal.pone.0031379.g001
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observed/expected CpG ratio, and the binding sites for several
groups of transcription factors [18]. Transcription factor EGR1 is
related to the inducible transcription of heparanase gene in T cells
[34], whereas the ubiquitous transcription factor Sp1 is associated
with its basal transcription [18]. In this study, we designed three
siRNAs targeting the heparanase promoter region containing
CpG loci and Sp1 binding site, while the siH3-targeted region
(29/+10 bp surrounding heparanase TSS locating at 101 bp
upstream of ATG) was also adjacent to the binding site of EGR1.
However, our evidence showed that transfection of these siRNAs
induced neither methylation of CpG nor heterochromatin
formation on heparanase promoter. ChIP analysis further ruled
out the changes in the binding of Sp1 and EGR1 on heparanase
promoter, and splice variant analysis ruled out the differential
splicing of the closest exon.
In fact, siRNAs targeting promoter regions fail to induce TGS
in certain instance [35]. Recent studies show that antigene RNAs
(agRNAs) targeting the TSS can block gene transcription of
human progesterone receptor (PR) [36,37], androgen receptor
(AR) [37], and huntingtin [37], suggesting that TSS in
chromosomal DNA provides predictable targets for inhibiting
gene expression with RNAs. In the current study, we demonstrat-
ed that siRNA and shRNA targeting the TSS induced TGS of
heparanase in human cancer cells, while the small RNAs targeting
the upstream promoter region containing CpG loci did not
suppress the expression of heparanase, suggesting that the loci they
targeted might not be susceptible to TGS. Moreover, we also
noted the similar efficiencies of siH3 and encoding region-targeted
siH4 in attenuating the expression and function of heparanase.
These results indicate the valuable role of TSS-targeted small
RNAs in the regulation of gene expression by TGS, especially
when the RNAs targeting upstream promoter region fail to
produce a marked effect.
A mechanism rather than genetic and epigenetic regulation
underlines the TGS of heparanase induced by TSS-targeted
siRNA in human cancer cells. Similarly, no methylation is
observed surrounding the TSS of AR and PR [34], and
agRNAs-mediated TGS occurs regardless of whether the promot-
er contains a TATA box [36,37]. Previous studies indicate that
TFIIB binds the core promoter DNA and directs RNA Pol II to
the TSS, promoting assembly of the functional transcription
preinitiation complex (PIC) [38]. In this study, we showed that
siRNAs targeting the TSS locating at 101 bp upstream of ATG
interfered with transcription initiation of heparanase, and the
concomitant loss of TFIIB and RNA Pol II suggested that the
siRNAs reduced the assembly of PIC formation at this TSS. It has
been indicated that when mammalian RNA polymerase binds to
DNA at TSS, it forms an open complex in which bases 29t o+2
are accessible to chemical agents that modify single-stranded
DNA, suggesting that TSS may be accessible to hybridization
[36,37]. Recent studies have indicated the presence of noncoding
promoter-associated RNA (pRNA) and the consequences of their
targeting by siRNAs in human cells [39,40]. Low-copy pRNAs are
recognized by the antisense strand of the siRNA and function as a
recognition motif to direct epigenetic silencing complexes to the
corresponding targeted promoters to mediate TGS in human cells
[39]. In addition, the formation of siRNA-pRNA complex with the
contribution of Ago2 is responsible for the reduced assembly of
functional PIC and blockade of transcription initiation in the c-
myc promoter [40]. Thus, whether pRNA exists to direct siH3-
induced TGS of heparanase warrants our further investigation.
Because an open complex is formed during the transcription of
every gene, it is feasible to directly design agRNAs to any gene that
has a characterized TSS [41]. Therefore, we believe that the TGS
strategy via TSS-targeted siRNA may also be applied to other
genes, which warrants our further investigation.
Ago protein complexes containing single-stranded small RNAs
are called mature RNA-induced silencing complex (RISC) [42].
Ago proteins have positively charged surfaces that are well suited
for binding siRNA and aligning it with the complementary target
sequence, suggesting that Ago proteins may play a central role in
the formation of RNA-induced initiation of TGS complex that
initiates the heterochromatin formation [37]. In this study, we
demonstrated that Ago1 and Ago2 were necessary to attenuate the
binding of RNA Pol II and TFIIB on heparanase promoter during
siH3-induced TGS of heparanase. Recent evidence indicates that
the interaction between RNA Pol II and the small RNA
machinery (Ago1, Ago2, piwi) affects heterochromatic silencing
in Drosophila [26]. In human cells, Ago1 associates with RNA Pol II
via protein-protein interactions and is required for dimethylation
of histone H3 at lysine 9 and TGS [32]. In this study, our data did
not show any direct protein-protein interaction between the RISC
(Ago1 and Ago2) and PIC (RNA Pol II and TFIIB) components
during siH3-induced TGS of heparanase, suggesting that different
association between RISC and PIC might be involved in variable
siRNA-induced TGS.
In experimental models, the cells expressing heparanase possess
a high potential for extravasation of tumor cells in vascular vessels
and are susceptible to develop a lung metastasis [43]. Apart from
its direct involvement in BM invasion by endothelial cells,
heparanase elicits an indirect angiogenic response through
releasing angiogenic growth factors, such as bFGF and VEGF
[3,4]. Thus, heparanase may facilitate tumor cell invasion and
neovascularization, both critical steps in tumor progression. In the
current study, we further demonstrated that TSS-targeted shRNA
Figure 2. siRNA induces transcription initiation arrest, but not DNA methylation or histone deacetylation, of heparanase promoter.
A and B, bisulfite sequencing and MSP revealed that transfection of siRNAs (100 nmol/L), siH1, siH2 and siH3, did not induce the methylation of CpG
islands of heparanase promoter in cancer cells. C, 72 hrs post-transfection, ChIP with distinct primer sets indicated that there were no PCR products
for ‘‘no-antibody’’ (No Ab) control, and the binding of H3K9me2, H3K27me3 and AcH3 on the heparanase promoter did not change after transfection
of siH2, siH3, siH4 or siScb in cancer cells. D, The binding of H3K9me2 and H3K27me3 was enriched on the promoter of p16 and RARb2 compared to
that on heparanase promoter in PC-3 cells, respectively. E, treatment of siH3- or siScb-transfected cancer cells with TSA (200 nmol/L), resulted in a
significant increase in the binding of AcH3 on the heparanase promoter, when compared to those treated with DMSO solvent control. F, cancer cells
were transfected with siRNAs and treated with 5-Aza-CdR (5 mmol/L) or TSA (200 nmol/L), resulting in no changes in siH3-induced heparanase
silencing. G, 72 hrs post-transfection, ChIP assay indicated that the binding of Sp1 and EGR1 on the heparanase promoter, did not change after
transfection of siH2, siH3, siH4 or siScb in cancer cells. H, ChIP assay with distinct primer sets indicated the decreased binding of RNA Pol II and TFIIB
on heparanase promoter in siH3-transfected cancer cells, but not in siH2- or siH4-transfected cells. I, ChIP assay indicated that the decreased RNA Pol
II or TFIIB binding was seen reproducibly and up to 7 days post-transfection of siH3 in cancer cells. J, qRT-PCR detection demonstrated that the
relative inclusion-to-exclusion ratio of the first exon of heparanase did not change after transfection of siH2, siH3, siH4 or siScb in cancer cells. The
symbol (#) indicates a significant decrease from untransfected control (mock) or siScb. The symbol (m) indicates a significant increase from the
binding on heparanase promoter. The symbol (D) indicates a significant increase from DMSO control.
doi:10.1371/journal.pone.0031379.g002
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invasion, metastasis and angiogenesis of cancer cells in vitro and in
vivo. Our findings suggest that induction of TGS by TSS-targeted
shRNA is a promising approach for the suppression of heparanase
gene function as well as illustrating its application in cancer
therapy.
In summary, in this study, we have shown that small RNAs
(siRNA or shRNA) targeting the TSS locating at 101 bp upstream
of the translation start site can significantly suppress transcription
initiation, but not induce epigenetic changes, to mediate TGS of
heparanase and attenuate the invasion, metastasis and angiogen-
esis of human cancer cells in vitro and in vivo. The consistent
findings in cell lines originating from different cancer types imply
the generality of this strategy in cancer therapy. Although low
levels of alternative upstream transcribed heparanase transcript
were also noted in this study, its exact TSS location, 59-flanking
region and promoter sequence still remain exclusive so far. Until
these items have been elucidated, the effects of siRNAs targeting
this TSS and promoter can be further investigated. We believe
that TSS-targeted small RNAs have the potential to be developed
into a useful approach for inhibition of metastatic growth of
human cancer.
Materials and Methods
Cell culture
Human bladder cancer cell line EJ (MGH-U1) was obtained
from the Institute of Urology, Peking University (Beijing, China).
Human prostate cancer cell line PC-3 (CRL-1435) and endothelial
cell line HUVEC (CRL-1730) were purchased from American
Type Culture Collection (Rockville, MD). Human gastric cancer
cell line SGC-7901 was obtained from the Type Culture
Collection of Chinese Academy of Sciences (Shanghai, China).
The cells were grown in RPMI1640 medium (Life Technologies,
Inc., Gaithersburg, MD) supplemented with 10% fetal bovine
serum (FBS, Life Technologies, Inc.), and applied for transcfection
or treatment with 5-Aza-CdR (Sigma, St. Louis, MO) or TSA
(Sigma) as previously described [44,45].
siRNA transfection
Three 21-nucleotide siRNAs targeting TSS (locating at 101 bp
upstream of ATG) or more upstream regions of heparanase
promoter, siH1 (2174/2155 bp), siH2 (2134/2115 bp) and
siH3 (29/+10 bp), were designed according to the TSS site, CpG
loci and transcription factor binding sites within heparanase
promoter. These siRNAs were chemically synthesized and
transfected with Genesilencer Transfection Reagent (Genlantis,
San Diego, CA) according to the suggested concentrations of
manufacturer (RiboBio Co. Ltd, Guangzhou, China). The siH4
(+1496/+1515 bp) targeting the encoding region of heparanase
served as a positive control [46]. The siNC and siSCb were
applied as controls. The untransfected cells were applied as a mock
control. For knocking down of Ago1 and Ago2, the cells were co-
transfected with the corresponding siRNAs. The nucleotide
sequences of these siRNAs were shown in Table S1.
shRNA constructs and stable transfection
Three sets of oligonucleotides encoding shRNAs complemen-
tary to TSS (locating at 101 bp upstream of ATG), upstream
promoter and encoding regions of heparanase were subcloned into
pGenesil-1 (Genesil Biotechnology, Wuhan, China). Annealed
Figure 3. Ago1 and Ago2 are involved in TGS of heparanase induced by TSS-targeted siRNA. A and B, knocking down of Ago1 or Ago2
restored the siH3-induced TGS of heparanase in cancer cells, respectively. C and D, ChIP assay indicated that 72 hrs post-transfection of siH3, but not
of siScb, the association of Ago1 and Ago2 on the heparanase promoter increased in cancer cells, which was abolished by knocking down of Ago1
and Ago2, respectively. E, ChIP assay indicated that silencing of Ago1 or Ago2 restored the binding of RNA Pol II and TFIIB on heparanase promoter in
cancer cells. F, nuclear run-on assay indicated that the upstream transcribed mRNA (containing Exon 1) presented at a low level compared to total
heparanase mRNA, and the nascent transcription of total heparanase mRNA, but not the mRNA initiated from upstream alternative TSS, decreased
after transfection of siH3 into cancer cells for 72 hrs, which was restored by knocking down of Ago1 or Ago2. The symbols (# and D) indicate a
significant decrease and a significant increase from siScb, respectively. The symbol (*) indicates a significant decrease from siNC.
doi:10.1371/journal.pone.0031379.g003
Figure 4. RNAi machinery interacts indirectly with transcription
preinitiation complex in siH3-induced TGS of heparanase. A,
co-immunoprecipitation analysis with pull-down by anti-RNA Pol II or
anti-TFIIB antibodies indicated that siH3 or siScb did not attenuate the
interaction between RNA Pol II and TFIIB in cancer cells. In addition,
Ago1 or Ago2 did not directly interact with either RNA Pol II or TFIIB in
siScb- and siH3-transfected cancer cells. B, co-immunoprecipitation
analysis with pull-down by anti-Ago1 or anti-Ago2 antibodies did not
co-immunoprecipite RNA Pol II or TFIIB from siScb- and siH3-transfected
cancer cells.
doi:10.1371/journal.pone.0031379.g004
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31379oligonucleotides were cloned downstream of U6 promoter as
shown in Table S1. The plasmids shP2 (2134/2115 bp), shP3
(29/+10 bp), shCd (+1496/+1515 bp) and shScb were verified by
DNA sequencing and transfected into cancer cells with Genesi-
lencer Transfection Reagent (Genlantis). Stable cancer cell lines
transfected with shRNA were screened by administration of G418
(Invitrogen, Carlsbad, CA).
Dual-luciferase reporter assay for heparanase promoter
activity
The human heparanase promoter-luciferase reporter constructs
containing a series of deletion fragments from the 59-flanking
region of heparanase promoter, pGL3/HPA-3.5, pGL3/HPA-0.7
and pGL3/HPA-0.3, were kindly provided by Dr. Xiulong Xu
(Department of General Surgery, Rush University Medical
Center, Chicago, IL) [18]. Dual-luciferase reporter assay was
performed according to the manufacturer’s instructions (Promega,
Madison, WI). The luciferase activity was measured with a
luminometer (Lumat LB9507, Berthold Tech., Bad Wildbad,
Germany).
RT-PCR and real-time quantitative RT-PCR
RT-PCR was performed as previously described [46], with
PCR primers shown in Table S2. Real-time quantitative RT-PCR
(qRT-PCR) with SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA) was performed using ABI Prism
7700 Sequence Detector (Applied Biosystems). The fluorescent
signals were collected during extension phase, Ct values of the
samples were calculated, and the transcript levels were analyzed by
2
2DDCt method. For splice variant analysis [15], primers were
designed to amplify the transcripts containing the first exon of
heparanase, and the relative inclusion-to-exclusion ratio of the first
exon (Exon 1
+/Exon 1
2) was determined by measuring relative
abundance of Exon 1 to the remaining total heparanase transcripts
that did not contain Exon 1.
Western blot
Western blot was performed as previously described [46], with
antibodies specific for heparanase (InSight Company, Rehovot,
Israel), Sp1 (Abcam, Cambridge, MA), H3K9me2, H3K27me3,
AcH3, RNA Pol II (Upstate Biotechnology, Temacula, CA), Ago1,
Ago2 (Cell Signaling Technology, Inc., Danvers, MA), EGR1,
TFIIB, and GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA).
Methylation analysis of promoter CpG islands
Genomic DNA was extracted with the DNeasy Tissue Kit
(Qiagen Inc., Valencia, CA) according to the manufacturer’s
instructions. Sodium bisulfite modification of genomic DNA was
performed as previously described [5,6]. The methylation-specific
PCR (MSP) was undertaken to analyze the methylation of
heparanase promoter with primers spanning the CpG islands
(Table S1). The PCR products amplified with a pair of universal
primers were resorted to direct bisulfite sequencing (TakaRa Bio.,
Inc., Shiga, Japan).
Chromatin immunoprecipitation
ChIP assay was performed according to the manufacture’s
instructions of the EZ-ChIP kit (Upstate Biotechnology). The PCR
primers were designed by Premier Primer 5.0 software to amplify
three adjacent regions (Table S2), 2183/+13, 2137/+52 and
26/+283, surrounding the heparanase TSS (locating at 101 bp
upstream of ATG). qPCR with SYBR Green PCR Master Mix
(Applied Biosystems) was performed using ABI Prism 7700
Sequence Detector (Applied Biosystems). The amount of immu-
noprecipitated DNA was calculated in reference to a standard
curve and normalized to input DNA.
Nuclear run-on assay
Nuclear run-on assays were performed based on the incorpo-
ration of biotin-16-uridine- 59-triphosphate (biotin-16-UTP) in
nascent transcripts as previously described [47]. Briefly, 5610
6
nuclei of siRNA-transfected cells were isolated and consequently
incubated in a reaction buffer containing rNTPs and biotin-16-
UTP (Roche, Indianapolis, IN, USA) at 30uC for 45 min. The
reaction was stopped by adding RNase-free DNase I (Sigma), and
the nuclei were lysed and treated with proteinase K (Sigma). Total
RNA was extracted using Trizol (Invitrogen), and biotinylated
nascent RNA was purified using agarose-conjugated streptavidin
beads (Invitrogen). Beads were then eluted, and biotinylated RNA
was isolated for RT-PCR and qRT-PCR assays.
Co-immunoprecipitation
Co-immunoprecipitation was performed as previously described
[48], with antibodies specific for RNA Pol II, TFIIB, Ago1, Ago2
or unspecific IgG (Santa Cruz Biotechnology). The bead-bound
proteins were released by boiling the protein A-Sepharose beads
(Santa Cruz Biotechnology) in 16SDS-PAGE loading buffer and
analyzed by western blot.
Cell viability, colony formation, adhesion and invasion
assay
Cell viability was monitored by 2-(4,5-dimethyltriazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT, Sigma) colorimetric assay
[46]. Colony formation ratios and cell adhesion on 96-well plates
precoated with matrigel (BD Biosciences, Franklin Lakes, NJ) were
measured as previously described [46]. The Boyden chamber
technique (transwell analysis) with matrigel-coated filters was
performed for cell invasion assay [42].
In vitro angiogenesis assay
The endothelial tube–like formation assay of HUVEC cells was
performed as previously described [46]. The bFGF levels were
examined with an enzyme-linked immunosorbent assay kit
(Cusabio Biotech Co., Ltd, China).
Figure 5. Stable transfection of heparanase TSS-targeted shRNA attenuates the proliferation, adhesion, invasion and angiogenesis
of cancer cells in vitro.A , MTT colorimetry indicated that stable transfection of shP3 or shCd, but not of shP2 or shScb, attenuated the proliferation
of PC-3, EJ and SGC-7901 cells. B and C, colony formation assay indicated that transfection of shP3 and shCd, but not of shP2 or shScb, attenuated
the in vitro proliferation of PC-3, EJ and SGC-7901 cells. D and E, transwell analysis indicated that the PC-3, EJ and SGC-7901 cells transfected with
shP3 or shCd, but not with shP2 or shScb, possessed an impaired invasion capacity. F, in the adhesion assay, PC-3, EJ and SGC-7901 cells transfected
with shP3 or shCd, but not with shP2 or shScb, exhibited markedly reduced ability in adhesion to the precoated matrigel. G and H, endothelial cells
were treated with the medium preconditioned by stable transfection of PC-3, EJ and SGC-7901 cells with shP3 or shCd, but not with shScb, resulting
in suppressed tube formation on matrigel. I, the release of bFGF from PC-3, EJ and SGC-7901 cells was attenuated after transfection of shP3 or shCd,
but not of shScb. The symbol (#) indicates a significant decrease from empty vector-transfected cells (mock).
doi:10.1371/journal.pone.0031379.g005
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PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31379In vivo metastasis assay
All animal experiments were approved by the Animal Care
Committee of Tongji Medical College (approval number:
Y20080290). For the in vivo tumor growth studies, 2-month-old
male nude mice (n=6 per group) were injected subcutaneously in
the lower back with 1610
6 cancer cells stably transfected with
shRNAs. One month later, mice were sacrificed and examined for
tumor weight, gene expression, and angiogenesis. The peritoneal
metastasis (3610
6 cancer cells per mouse) and experimental
metastasis (0.4610
6 cancer cells per mouse) studies were
performed with 2-month-old male nude mice as previously
described [49,50].
Immunohistochemistry
Immunohistochemical staining was performed as previously
described [51], with antibodies specific for CD31, MMP-9, VEGF
(Santa Cruz Biotechnology; 1:200 dilutions) or heparanase
(InSight Company; 1:100 dilution).
Statistical analysis
Unless otherwise stated, all data were shown as mean 6
standard error of the mean (SEM). Statistical significance (P,0.05)
was determined by t test or analysis of variance (ANOVA) followed
by assessment of difference using SPSS 12.0 software (SPSS Inc.,
Chicago, IL).
Supporting Information
Figure S1 Schematic location of alternative heparanase
TSS. The transcription of heparanase gene can be initiated from
two different TSS sites, resulting in two mRNA species, which
contain Exon 1 or not, respectively. The location and promoter
region of former TSS remain unknown, while the later TSS is
located at or nearly close to 101 bp upstream of the translation
start site (ATG).
(DOC)
Figure S2 Target specificity of heparanase TSS-targeted
siRNA. Cancer cells were transfected with 10–100 nmol/L of
siH3, siNC (100 nmol/L) and siScb (100 nmol/L) or left
untreated. Cells were collected at 72 hrs post-transfection. qRT-
PCR indicated that the expression of non-downstream genes of
heparanase, PCNA and cyclin D1, was not affected by transfection
of siH3, siNC or siScb.
(DOC)
Figure S3 Heparanase TSS-targeted siRNA does not
influence the expression of epigenetic and transcrip-
tionally active chromatin marks. Cancer cells were trans-
fected with 100 nmol/L of siH3 or siScb for various duration as
indicated. Western blot revealed that transfection of siH3 or siScb
did not affect the expression of H3K9me2, H3K27me3, AcH3,
RNA Pol II, TFIIB, Sp1 or EGR1 in cancer cells.
(DOC)
Figure S4 Establishment of stable cell lines transfected
with heparanase TSS-targeted shRNA. The shRNA con-
structs targeting TSS (locating at 101 bp upstream of the
translation start site), upstream promoter and encoding regions
of heparanase, shP2 (2134/2115 bp), shP3 (29/+10 bp), shCd
(+1496/+1515 bp) and shScb, were transfected into cultured
cancer cell lines PC-3, EJ and SGC-7901, respectively. A, 72 hrs
post-transfection, the transfection efficiency was monitored by the
reporter gene, enhanced green fluorescent protein (EGFP), within
the vectors. B, stable cell lines were established by administration
of G418. RT-PCR (left panel) and western blot (right panel)
demonstrated that stable transfection of shP3 or shCd resulted in
attenuated mRNA and protein levels of heparanase in cancer cells.
C, qRT-PCR further indicated that the heparanase mRNA levels
in cancer cells were attenuated by stable transfection of shP3 or
shCd. The symbol (#) indicates a significant decrease from vector
transfection (mock) group.
(DOC)
Table S1 Sequences of small interfering RNAs and
short hairpin RNAs.
(DOC)
Table S2 Primers sets used for RT-PCR, ChIP and
qPCR.
(DOC)
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